NASDAQ:PRTG - Nasdaq - VGG7185A1369 - Common Stock - Currency: USD
NASDAQ:PRTG (3/3/2025, 5:20:01 PM)
4.14
-0.37 (-8.2%)
The current stock price of PRTG is 4.14 USD. In the past month the price decreased by -6.12%. In the past year, price decreased by -63.02%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.9 | 373.71B | ||
AMGN | AMGEN INC | 15.68 | 166.89B | ||
GILD | GILEAD SCIENCES INC | 25.16 | 144.52B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1666.59 | 124.16B | ||
REGN | REGENERON PHARMACEUTICALS | 15.01 | 74.87B | ||
ARGX | ARGENX SE - ADR | 241.32 | 37.83B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.41B | ||
BNTX | BIONTECH SE-ADR | N/A | 26.75B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.20B | ||
BIIB | BIOGEN INC | 8.6 | 20.65B | ||
NTRA | NATERA INC | N/A | 18.89B | ||
GMAB | GENMAB A/S -SP ADR | 24.69 | 14.59B |
Portage Biotech Inc is a VG-based company operating in Biotechnology industry. Portage Biotech Inc. is a clinical-stage immuno-oncology company. The firm is engaged in advancing therapies to improve long-term treatment response, and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. The Company’s portfolio consists of four platforms, with lead programs consisting of invariant natural killer T-cell (iNKT) engagers and a suite of treatments targeting the adenosine pathway. Within these four platforms, the Company has nine product candidates, of which five are pre-clinical and four of which are clinical stage. The Company’s portfolio also includes small molecule adenosine inhibitors, such as PORT-6, PORT-7, PORT-8 and PORT-9, which represent targeting the adenosine pathway.
PORTAGE BIOTECH INC
Clarence Thomas Building, P.O. Box 4649, Road Town
Tortola ONTARIO VG1110 VG
CEO: Ian Walters
Employees: 7
Company Website: https://portagebiotech.com/
Investor Relations: http://ir.portagebiotech.com
Phone: 4167377600
The current stock price of PRTG is 4.14 USD. The price decreased by -8.2% in the last trading session.
The exchange symbol of PORTAGE BIOTECH INC is PRTG and it is listed on the Nasdaq exchange.
PRTG stock is listed on the Nasdaq exchange.
PORTAGE BIOTECH INC (PRTG) has a market capitalization of 6.83M USD. This makes PRTG a Nano Cap stock.
PORTAGE BIOTECH INC (PRTG) currently has 7 employees.
PORTAGE BIOTECH INC (PRTG) has a support level at 3.51 and a resistance level at 4.51. Check the full technical report for a detailed analysis of PRTG support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PRTG does not pay a dividend.
PORTAGE BIOTECH INC (PRTG) will report earnings on 2025-08-13, after the market close.
PORTAGE BIOTECH INC (PRTG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-129.8).
The outstanding short interest for PORTAGE BIOTECH INC (PRTG) is 2.85% of its float. Check the ownership tab for more information on the PRTG short interest.
ChartMill assigns a technical rating of 1 / 10 to PRTG. When comparing the yearly performance of all stocks, PRTG is a bad performer in the overall market: 87.65% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to PRTG. While PRTG seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months PRTG reported a non-GAAP Earnings per Share(EPS) of -129.8. The EPS decreased by -403.1% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -1357.19% | ||
ROE | -2830.59% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 43% to PRTG. The Buy consensus is the average rating of analysts ratings from 6 analysts.